Senseonics Holdings, Inc., formerly ASN Technologies, Inc., is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. It provides continuous glucose monitoring (CGM) system, for which Eversense is designed to measure glucose levels in people with diabetes for a period of approximately 90 days. It focuses on initiating a single pivotal clinical trial in the United States. It focuses on marketing and selling of Eversense in the United States. Its Eversense consists of three components, such as a small smart sensor inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user's mobile device, such as a smartphone, apple watch or tablet.